201 related articles for article (PubMed ID: 29678530)
1. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.
Kiess AP; Wolchok JD; Barker CA; Postow MA; Tabar V; Huse JT; Chan TA; Yamada Y; Beal K
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):368-75. PubMed ID: 25754629
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity.
Diao K; Bian SX; Routman DM; Yu C; Ye JC; Wagle NA; Wong MK; Zada G; Chang EL
J Neurooncol; 2018 Sep; 139(2):421-429. PubMed ID: 29696531
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiosurgery for single brain metastases from non-small cell lung cancer: progression of extracranial disease correlates with distant intracranial failure.
Kress MA; Oermann E; Ewend MG; Hoffman RB; Chaudhry H; Collins B
Radiat Oncol; 2013 Mar; 8():64. PubMed ID: 23510318
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol.
Wang Y; Wang X; Guan Y; Song Y; Zhuang H; Wang E
Thorac Cancer; 2020 May; 11(5):1361-1364. PubMed ID: 32163662
[TBL] [Abstract][Full Text] [Related]
6. Integrating Overall Survival and Tumor Control Probability Models to Predict Local Progression After Brain Metastasis Radiosurgery.
Simon AB; Quezada J; Mohyeldin A; Harris J; Shi M; Seyedin S; Sehgal V; Chen AM
Adv Radiat Oncol; 2024 Jun; 9(6):101474. PubMed ID: 38681893
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Five Years Recurrence-Free Survival after Successful Multidisciplinary Treatment for Simultaneous Brain Metastasis and Heterochronic Small Intestinal Metastasis from Lung Cancer].
Wada T; Orimoto N; Tsurui K; Suda T; Saito H; Nagakawa Y
Gan To Kagaku Ryoho; 2024 Apr; 51(4):439-441. PubMed ID: 38644315
[TBL] [Abstract][Full Text] [Related]
8. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
Su Q; Zhang XC; Wang DY; Zhang HR; Zhu C; Hou YL; Liu JL; Gao ZH
Int Immunopharmacol; 2018 Jun; 59():328-338. PubMed ID: 29679857
[TBL] [Abstract][Full Text] [Related]
9. Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
Dumenil C; Massiani MA; Dumoulin J; Giraud V; Labrune S; Chinet T; Giroux Leprieur E
PLoS One; 2018; 13(4):e0195945. PubMed ID: 29684049
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.
Costantini A; Corny J; Fallet V; Renet S; Friard S; Chouaid C; Duchemann B; Giroux-Leprieur E; Taillade L; Doucet L; Nguenang M; Jouveshomme S; Wislez M; Tredaniel J; Cadranel J
ERJ Open Res; 2018 Apr; 4(2):. PubMed ID: 29692997
[TBL] [Abstract][Full Text] [Related]
11. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab.
Halvorsen AR; Sandhu V; Sprauten M; Flote VG; Kure EH; Brustugun OT; Helland Å
Acta Oncol; 2018 Sep; 57(9):1225-1231. PubMed ID: 29683761
[TBL] [Abstract][Full Text] [Related]
13. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S
Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
[TBL] [Abstract][Full Text] [Related]
14. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
Bins S; Basak EA; El Bouazzaoui S; Koolen SLW; Oomen-de Hoop E; van der Leest CH; van der Veldt AAM; Sleijfer S; Debets R; van Schaik RHN; Aerts JGJV; Mathijssen RHJ
Br J Cancer; 2018 May; 118(10):1296-1301. PubMed ID: 29695768
[TBL] [Abstract][Full Text] [Related]
15. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Joseph RW; Elassaiss-Schaap J; Kefford R; Hwu WJ; Wolchok JD; Joshua AM; Ribas A; Hodi FS; Hamid O; Robert C; Daud A; Dronca R; Hersey P; Weber JS; Patnaik A; de Alwis DP; Perrone A; Zhang J; Kang SP; Ebbinghaus S; Anderson KM; Gangadhar TC
Clin Cancer Res; 2018 Oct; 24(20):4960-4967. PubMed ID: 29685882
[No Abstract] [Full Text] [Related]
16. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
17. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
18. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
Yen CC; Su HC; Chu CY; Lai SJ; Yan JJ; Su WP; Su WC
Lung Cancer; 2018 Jun; 120():149-151. PubMed ID: 29681404
[No Abstract] [Full Text] [Related]
19. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.
Ishiba T; Hoffmann AC; Usher J; Elshimali Y; Sturdevant T; Dang M; Jaimes Y; Tyagi R; Gonzales R; Grino M; Pinski JK; Barzi A; Raez LE; Eberhardt WE; Theegarten D; Lenz HJ; Uetake H; Danenberg PV; Danenberg K
Biochem Biophys Res Commun; 2018 Jun; 500(3):621-625. PubMed ID: 29679564
[TBL] [Abstract][Full Text] [Related]
20. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
